STTR Phase I: Assessing an innovative Microfluidic Tissue Array device for applications in drug development and precision medicine

STTR 第一阶段：评估创新的微流控组织阵列设备在药物开发和精准医疗中的应用

• 批准号: 1938430
• 负责人: Lian Wang
• 金额: $ 22.47万
• 依托单位: Vivoz Biolabs LLC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-01-01 至 2022-03-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1938430&HistoricalAwards=false
• 关键词: STTR; Phase; Assessing; innovative; Microfluidic

The broader/commercial impact of this project aims to develop and commercialize a microfluidic device as a clinical platform to rapidly identify precise and effective therapies for individual cancer patients. Currently, prediction in precision medicine only has limited success, and the American Society of Clinical Oncology (ASCO) does not recommend using any specific drug sensitivity testing method alone to guide clinical treatment decision-making. Therefore, there is an urgent and unmet clinical need to create a rapidly implementable and clinically relevant experimental system that can rapidly and economically test the effects of therapeutic options on an individual patient's biopsy. The microfluidic platform developed in this project aims to rapidly and accurately evaluate drug efficacy using individual patient's biopsies, thus guiding personalized cancer treatment and leading to increased survival rates, reduced cost of healthcare, and improved quality of patient life. In addition, this technology will facilitate cancer drug discovery and development in terms of cost and time, leading to reduced costs of drug development. This Small Business Technology Transfer (STTR) Phase I project will develop a microfluidic system that preserves viability, structure, and other biological properties of tissue biopsy samples, providing a platform for efficient drug screening and determining the responsiveness of individual patient cancer samples to therapeutic drugs. Current precision medicine for cancer treatment is mainly prediction-based on cancer genomic data instead of direct test or validation of the responsiveness of patient cancer samples to drugs. Lack of rapid and accurate methods for such direct tests is a major obstacle in cancer treatment. To overcome this obstacle, Microfluidic Tissue Arrays (µFTA) will be developed to mimic physiological blood perfusion to maintain the native microenvironment of tumor samples. As a result, tumor tissues cultured in the µFTAs can preserve their in vivo biological properties. This project will establish the feasibility of setting up a robust assay in the µFTA for measuring tumor tissue response to drugs and assess initial correlation of the obtained data with in vivo results. The ultimate goal of this project is to develop a µFTA-based platform to directly evaluate the responsiveness of patient biopsy tissues to different therapies, thus providing drug selection guidance for individual patients.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

该项目的更广泛/商业影响旨在开发和商业化微流体设备作为临床平台，以快速识别单个癌症患者的精确和有效疗法。当前，精密医学的预测仅取得了有限的成功，美国临床肿瘤学会（ASCO）不建议仅使用任何特定的药物敏感性测试方法来指导临床治疗决策。因此，紧急且未满足的临床需要，可以创建快速实施的临床相关实验系统，该系统可以快速和经济地测试治疗选择对个体患者活检的影响。该项目中开发的微流体平台旨在快速，准确地使用个体患者的活检来评估药物有效性，从而指导个性化的癌症治疗，并提高存活率，降低医疗保健成本以及改善患者生活质量。此外，这项技术将在成本和时间上促进癌症药物发现和开发，从而导致药物开发成本降低。这个小型企业技术转移（STTR）I期项目将开发一个微流体系统，以保留组织活检样品的生存力，结构和其他生物学特性，为有效的药物筛查和确定个别患者癌症样品对治疗药物的反应性提供了一个平台。当前用于癌症治疗的精度医学主要基于癌症基因组数据，而不是直接检验或验证患者癌症对药物的反应性。这种直接测试缺乏快速准确的方法是癌症治疗的主要障碍。为了克服这一障碍，将开发微流体组织阵列（µFTA）以模仿生理血液灌注以维持肿瘤样品的天然微环境。结果，在µFTA中培养的肿瘤组织可以保留其体内生物学特性。该项目将建立在µFTA中建立可行的可行性，以测量肿瘤组织对药物的反应，并评估所获得的数据与体内结果的初始相关性。该项目的最终目标是开发一个基于µFTA的平台，以直接评估患者活检组织对不同疗法的反应性，从而为个别患者提供药物选择指南。该奖项反映了NSF的法定任务，并通过使用基金会的知识分子和更广泛的影响审查审查标准来通过评估来诚实地通过评估来诚实地支持。